A program between Exogene and SmithKline Beecham (SKB) studying Exogene’shemoglobin technology has been extended for another year following promising first-yearresults.

Financial details of the arrangement were not disclosed.

The program is seeking to improve the manufacture of certain SKB products usingExogene’s oxygen-enhancing technology that can increase yields of recombinantproteins made from genetically engineered cells.

Using this approach, the Monrovia, Calif., company offers new ways to significantlyreduce production costs without plant or equipment modifications.

No Comments